BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BBIO BridgeBio Pharma, Inc.

盘前交易 08-16 05:34:44 EDT

24.96

+0.71

+2.93%

最高25.19	最低24.23	成交量98.40万
今开24.84	昨收24.25	日振幅3.96%
总市值46.93亿	流通市值30.38亿	总股本1.88亿
成交额2,452万	换手率0.81%	流通股本1.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BBIO","market":"US","secType":"STK","nameCN":"BridgeBio Pharma, Inc.","latestPrice":24.96,"timestamp":1723752000000,"preClose":24.25,"halted":0,"volume":983990,"delay":0,"floatShares":121718216,"shares":188032738,"eps":-2.577907,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.71,"latestTime":"08-16 05:34:44 EDT","open":24.84,"high":25.19,"low":24.23,"amount":24523237.88957,"amplitude":0.039588,"askPrice":28.22,"askSize":100,"bidPrice":20.04,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.577907,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1723815000000},"adr":0,"listingDate":1561608000000,"adjPreClose":24.96,"postHourTrading":{"tag":"盘后","latestPrice":24.96,"preClose":24.96,"latestTime":"18:58 EDT","volume":25890,"amount":646119.69,"timestamp":1723762716077},"volumeRatio":0.8106050857937677,"impliedVol":0.7165,"impliedVolPercentile":0.5777},"requestUrl":"/m/hq/s/BBIO/tweets","defaultTab":"tweets","newsList":[{"id":"2457882895","title":"美国研究综述-安进、Atkore、Moneylion","url":"https://stock-news.laohu8.com/highlight/detail?id=2457882895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457882895?lang=zh_cn&edition=full","pubTime":"2024-08-07 16:03","pubTimestamp":1723017814,"startTime":"0","endTime":"0","summary":"    路透8月7日 - 华尔街证券分析师周三调整了对安进、Atkore 和 Moneylion 等几家美国上市公司的评级和目标价。要闻             * 安进公司  ：加拿大皇家银行将其目标价从332美元上调至362美元             * Atkore Inc   ：加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BLMN","ADUS","ALGT","ATKR","AZPN","ALIT","BK4020","BLDR","RDDT","AEP","LU0868494708.USD","BR","ALAB","AZTA","AMGN","H","IE0002141913.USD","BAX","LU1894683348.USD","ADTN","BWIN","IE00B7SZL793.SGD","BCC","BL","ARMK","CAT","AVNT","CBT","AMWL","CERT","BK4566","XAIR","BEAM","CAR","LU1989773731.SGD","BBIO","IE00B775SV38.USD","AMH","CRBU","BBWI","BRBR","ANAB","LUMN","ATI","ACAD","BK4090","BRKR","LU2098885051.SGD","BK4149"],"gpt_icon":1},{"id":"2457775988","title":"Bridgebio Pharma, Inc.盘中异动 股价大跌6.40%报24.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457775988","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457775988?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:41","pubTimestamp":1722865319,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时41分，Bridgebio Pharma, Inc.股票出现波动，股价快速下跌6.40%。截至发稿，该股报24.51美元/股，成交量11.1931万股，换手率0.06%，振幅2.44%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为2.33%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805214159957f3497&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805214159957f3497&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","BBIO","BK4588","BK4505"],"gpt_icon":0},{"id":"2456281462","title":"Bridgebio Pharma, Inc.盘中异动 大幅跳水6.68%报24.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456281462","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456281462?lang=zh_cn&edition=full","pubTime":"2024-08-02 21:31","pubTimestamp":1722605509,"startTime":"0","endTime":"0","summary":"北京时间2024年08月02日21时31分，Bridgebio Pharma, Inc.股票出现异动，股价大幅下挫6.68%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.74%。其相关个股中，Exicure, Inc.、Anew Medical Inc C/Wts 21/06/2029 、Moleculin Biotech, Inc.涨幅较大，Exicure, Inc.、Dermata Therapeutics, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为250.99%、47.57%、17.29%，振幅较大的相关个股有Exicure, Inc.、Coya Therapeutics, Inc.、Travere Therapeutics, Inc.，振幅分别为19.03%、9.64%、9.47%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080221314995780c33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080221314995780c33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4139","BBIO","BK4505"],"gpt_icon":0},{"id":"2456143998","title":"BridgeBio Pharma Inc 公布截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2456143998","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456143998?lang=zh_cn&edition=full","pubTime":"2024-08-01 22:24","pubTimestamp":1722522283,"startTime":"0","endTime":"0","summary":"   * BridgeBio Pharma Inc   报告，截至6月底的季度调整后每股亏损39美分，高于去年同期的每股-98美分。华尔街预期为每股亏损 1.27 美元至-82 美分。* 营收同比增长 32.1%，达到 217 万美元；分析师预期为 357 万美元。* BridgeBio Pharma 公司公布的本季度每股收益为亏损 39 美分。* 该公司当季亏损 7346 万美元。* BridgeBio Pharma Inc 本季度股价上涨了 2.4%，今年迄今为止亏损了 35.7%。8月1日 - 预测变化   * 过去三个月，分析师的平均盈利预期下降了约 6.7%。华尔街对 BridgeBio Pharma Inc 的 12 个月目标价中位数为 48.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BBIO","BK4139","BK4505","BK4585"],"gpt_icon":0},{"id":"2456266169","title":"Bridgebio Pharma, Inc.盘中异动 股价大涨5.01%报27.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456266169","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456266169?lang=zh_cn&edition=full","pubTime":"2024-08-01 02:54","pubTimestamp":1722452073,"startTime":"0","endTime":"0","summary":"北京时间2024年08月01日02时54分，Bridgebio Pharma, Inc.股票出现异动，股价急速拉升5.01%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.84%。其相关个股中，Molecular Partners Ag、Alpha Tau Medical Ltd C/Wts 、木薯科学涨幅较大，Cns Pharmaceuticals, Inc.、Salarius Pharmaceuticals, Inc.、Imunon, Inc.较为活跃，换手率分别为736.30%、169.19%、157.20%，振幅较大的相关个股有Molecular Partners Ag、Renovaro Inc.、Alpha Tau Medical Ltd C/Wts ，振幅分别为89.73%、79.10%、52.94%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240801025433941fca9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240801025433941fca9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","BK4588","BBIO","BK4505"],"gpt_icon":0},{"id":"2452148079","title":"Bridgebio Pharma, Inc.盘中异动 早盘股价大跌5.11%报26.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452148079","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452148079?lang=zh_cn&edition=full","pubTime":"2024-07-18 22:35","pubTimestamp":1721313303,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日22时35分，Bridgebio Pharma, Inc.股票出现异动，股价快速下跌5.11%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.63%。其相关个股中，Onconetix, Inc.、Silo Pharma, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 涨幅较大，Silo Pharma, Inc.、Onconetix, Inc.、Bionomics Ltd Ads Each Rep 180 Ord Shs较为活跃，换手率分别为1774.81%、999.66%、142.99%，振幅较大的相关个股有Silo Pharma, Inc.、Onconetix, Inc.、Nkgen Biotech, Inc.，振幅分别为93.33%、86.24%、37.39%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718223503941f85a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718223503941f85a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO","BK4139","BK4505","BK4588","BK4585"],"gpt_icon":0},{"id":"2452161345","title":"Bridgebio Pharma, Inc.盘中异动 大幅跳水5.13%报27.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452161345","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452161345?lang=zh_cn&edition=full","pubTime":"2024-07-17 23:42","pubTimestamp":1721230939,"startTime":"0","endTime":"0","summary":"北京时间2024年07月17日23时42分，Bridgebio Pharma, Inc.股票出现波动，股价大幅下跌5.13%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为2.06%。其相关个股中，Aptevo Therapeutics Inc.、Geovax Labs Inc C/Wts 29/09/2025、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Aptevo Therapeutics Inc.、Aditxt, Inc.、Longeveron Inc.较为活跃，换手率分别为3064.99%、1331.73%、281.26%，振幅较大的相关个股有Aptevo Therapeutics Inc.、Aditxt, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ，振幅分别为76.39%、46.25%、43.75%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407172342209681db52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407172342209681db52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BBIO","BK4139","BK4505","BK4585"],"gpt_icon":0},{"id":"2452794788","title":"Bridgebio Pharma, Inc.盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452794788","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452794788?lang=zh_cn&edition=full","pubTime":"2024-07-17 03:53","pubTimestamp":1721159612,"startTime":"0","endTime":"0","summary":"北京时间2024年07月17日03时53分，Bridgebio Pharma, Inc.股票出现波动，股价急速拉升5.03%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Silo Pharma, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 涨幅较大，Silo Pharma, Inc.、Scisparc Ltd.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为4573.11%、1357.55%、436.72%，振幅较大的相关个股有Geovax Labs Inc C/Wts 29/09/2025、Silo Pharma, Inc.、Scisparc Ltd.，振幅分别为79.41%、75.69%、72.88%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407170353339681d468&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407170353339681d468&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BBIO","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2446563258","title":"Bridgebio Pharma, Inc.盘中异动 快速上涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446563258","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446563258?lang=zh_cn&edition=full","pubTime":"2024-06-28 00:47","pubTimestamp":1719506850,"startTime":"0","endTime":"0","summary":"北京时间2024年06月28日00时47分，Bridgebio Pharma, Inc.股票出现异动，股价大幅拉升5.01%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.52%。其相关个股中，Geovax Labs Inc C/Wts 29/09/2025、Geovax Labs, Inc.、Onconetix, Inc.涨幅较大，Geovax Labs, Inc.、Kala Bio, Inc.、Nls Pharmaceutics Ltd.较为活跃，换手率分别为2651.11%、367.17%、338.63%，振幅较大的相关个股有Geovax Labs Inc C/Wts 29/09/2025、Geovax Labs, Inc.、Nls Pharmaceutics Ltd.，振幅分别为322.04%、127.05%、81.43%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628004730968178c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628004730968178c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BBIO","BK4585","BK4505","BK4139"],"gpt_icon":0},{"id":"2446007110","title":"BUZZ-Alnylam 因心脏病药物在关键研究中获得成功而跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2446007110","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446007110?lang=zh_cn&edition=full","pubTime":"2024-06-25 01:42","pubTimestamp":1719250931,"startTime":"0","endTime":"0","summary":" (更新)    6月24日 - ** Alnylam Pharmaceuticals  股价大涨40%至231.64美元，创下自2023年2月以来的最高水平 。** 如果涨势保持，市值将增加80多亿美元** 该公司称其心脏病药物vutrisiran在一项受到密切关注的后期研究中达到了  主要目标和所有次要目标** 该药物vutrisiran有助于将一种被称为ATTR-CM的罕见心脏病患者的死亡人数和心脏相关住院治疗人数减少33%。** ALNY 公司的药物通过关闭转甲状腺素蛋白的不规则生产而发挥作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BUZZ","BK4588","IONS","BK4505","ALNY","BK4535","BK4556","BBIO","LU1861559042.SGD","BK4548","LU1861558580.USD","NTLA","BK4585"],"gpt_icon":0},{"id":"2445749330","title":"Bridgebio Pharma, Inc.盘中异动 大幅下跌11.15%报24.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445749330","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445749330?lang=zh_cn&edition=full","pubTime":"2024-06-24 21:31","pubTimestamp":1719235903,"startTime":"0","endTime":"0","summary":"北京时间2024年06月24日21时31分，Bridgebio Pharma, Inc.股票出现异动，股价快速跳水11.15%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。消息层面，截至21时31分，《TD Cowen维持BridgeBio Pharma买入评级》资讯为影响Bridgebio Pharma, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406242131439f600055&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406242131439f600055&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","BK4585","BBIO","BK4588"],"gpt_icon":0},{"id":"2443676921","title":"Bridgebio Pharma, Inc.盘中异动 股价大跌5.00%报27.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443676921","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443676921?lang=zh_cn&edition=full","pubTime":"2024-06-14 22:17","pubTimestamp":1718374636,"startTime":"0","endTime":"0","summary":"北京时间2024年06月14日22时17分，Bridgebio Pharma, Inc.股票出现异动，股价急速跳水5.00%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Biocardia Inc C/Wts 06/08/2024、Cns Pharmaceuticals, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Longeveron Inc.、Bio-Path Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为712.57%、201.55%、164.44%，振幅较大的相关个股有Cns Pharmaceuticals, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Kyverna Therapeutics, Inc.，振幅分别为88.40%、57.51%、39.40%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240614221716af8da34f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240614221716af8da34f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BBIO","BK4585","BK4505"],"gpt_icon":0},{"id":"2442554211","title":"Bridgebio Pharma, Inc.盘中异动 早盘急速拉升5.06%报28.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442554211","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442554211?lang=zh_cn&edition=full","pubTime":"2024-06-12 21:30","pubTimestamp":1718199059,"startTime":"0","endTime":"0","summary":"北京时间2024年06月12日21时30分，Bridgebio Pharma, Inc.股票出现波动，股价大幅上涨5.06%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.37%。其相关个股中，Avidity Biosciences, Inc.、Molecular Partners Ag、Passage Bio, Inc.涨幅较大，Tonix Pharmaceuticals Holding Corp.、Tracon Pharmaceuticals, Inc.、Jaguar Health, Inc.较为活跃，换手率分别为35.58%、18.76%、3.50%，振幅较大的相关个股有Xortx Therapeutics Inc.、Passage Bio, Inc.、Curevac N.V.，振幅分别为20.93%、18.35%、7.06%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612213059941ee092&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612213059941ee092&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO","BK4585","BK4588","BK4505","BK4139"],"gpt_icon":0},{"id":"2441222323","title":"HC Wainwright &amp; Co.：重申BridgeBio Pharma(BBIO.US)评级，由买入调整至买入评级, 目标价由43.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441222323","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441222323?lang=zh_cn&edition=full","pubTime":"2024-06-05 19:28","pubTimestamp":1717586918,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BBIO","BK4139","BK4505","BK4585"],"gpt_icon":0},{"id":"2440351452","title":"Bridgebio Pharma, Inc.盘中异动 股价大涨6.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2440351452","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440351452?lang=zh_cn&edition=full","pubTime":"2024-06-04 21:31","pubTimestamp":1717507918,"startTime":"0","endTime":"0","summary":"北京时间2024年06月04日21时31分，Bridgebio Pharma, Inc.股票出现异动，股价大幅上涨6.14%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Protagenic Therapeutics Inc C/Wts 29/04/2026 、Annexon, Inc.、Silo Pharma, Inc.涨幅较大，Bio-Path Holdings, Inc.、Fresh2 Group Limited、Equillium, Inc.较为活跃，换手率分别为35.50%、34.70%、20.10%，振幅较大的相关个股有Fresh2 Group Limited、康乃德生物、Equillium, Inc.，振幅分别为14.90%、14.03%、12.92%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406042131589f191681&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406042131589f191681&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BK4588","BK4505","BBIO"],"gpt_icon":0},{"id":"2440238766","title":"BUZZ-BridgeBio公司在遗传病治疗中期试验中取得积极进展，业绩攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2440238766","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440238766?lang=zh_cn&edition=full","pubTime":"2024-06-04 21:13","pubTimestamp":1717506790,"startTime":"0","endTime":"0","summary":"    6月4日 - ** 药物开发商BridgeBio Pharma   股价盘前上涨8%至31.29美元** 该公司称，其口服疗法 infigratinib 在一项中期试验中显示， ，软骨发育不全患者的身体比例有了显著改善。** 软骨发育症是一种遗传性骨骼生长障碍，会导致短肢侏儒症** BMO Capital Markets分析师认为，这些数据表明，infigratinib的后期试验数据很可能与BioMarin Pharmaceutical公司的  软骨发育不全药物Voxzogo相当或更胜一筹。** 截至上日收盘，股价累计下跌28.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN","BUZZ","IE0002270589.USD","BK4588","BK4566","IE00B19Z3B42.SGD","BK4585","BBIO","IE00B7SZLL34.SGD","BK4139","IE00B19Z3581.USD","BK4505"],"gpt_icon":0},{"id":"2438308243","title":"坎托菲茨杰拉德公司：重申BridgeBio Pharma(BBIO.US)评级，由增持调整至增持评级, 目标价由70.00美元调整至70.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2438308243","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2438308243?lang=zh_cn&edition=full","pubTime":"2024-05-28 22:15","pubTimestamp":1716905759,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申BridgeBio Pharma(BBIO.US)评级，由增持调整至增持评级, 目标价由70.00美元调整至70.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405282216039ef9d093&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405282216039ef9d093&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO"],"gpt_icon":0},{"id":"2438308854","title":"坎托菲茨杰拉德公司：重申BridgeBio Pharma(BBIO.US)评级，由增持调整至增持评级, 目标价由70.00美元调整至70.","url":"https://stock-news.laohu8.com/highlight/detail?id=2438308854","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2438308854?lang=zh_cn&edition=full","pubTime":"2024-05-28 22:10","pubTimestamp":1716905405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBIO","BK4585","BK4588","BK4505","BK4139"],"gpt_icon":0},{"id":"2438377085","title":"BridgeBio Pharma Inc：瑞银将目标价格从51美元下调至47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2438377085","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2438377085?lang=zh_cn&edition=full","pubTime":"2024-05-28 21:26","pubTimestamp":1716902812,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma Inc：瑞银将目标价格从51美元下调至47美元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405282126559ef99743&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405282126559ef99743&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO"],"gpt_icon":0},{"id":"2435567168","title":"BridgeBio Pharma(BBIO.US)获Evercore ISI Group首次覆盖，给予优于大市评级, 目标价50.","url":"https://stock-news.laohu8.com/highlight/detail?id=2435567168","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2435567168?lang=zh_cn&edition=full","pubTime":"2024-05-14 17:17","pubTimestamp":1715678252,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK4505","BK4585","BK4588","EVR","BBIO","BK4127"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bridgebio.com","stockEarnings":[{"period":"1week","weight":0.0196},{"period":"1month","weight":-0.1467},{"period":"3month","weight":-0.1705},{"period":"6month","weight":-0.3292},{"period":"1year","weight":-0.1624},{"period":"ytd","weight":-0.3817}],"compareEarnings":[{"period":"1week","weight":0.0423},{"period":"1month","weight":-0.0209},{"period":"3month","weight":0.0446},{"period":"6month","weight":0.1072},{"period":"1year","weight":0.258},{"period":"ytd","weight":0.1636}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BridgeBio Pharma, Inc.于2019年5月17日成立为特拉华州公司。他们是一个由经验丰富的药物发现者，开发者和创新者组成的团队，致力于创造改变生命的药物，从源头上瞄准特征明确的遗传性疾病。他们确定和推进转化药物治疗患有孟德尔疾病的患者，这些疾病是由单一基因缺陷引起的疾病，以及具有明确遗传驱动因素的癌症。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.111762},{"month":2,"riseRate":0.4,"avgChangeRate":0.037273},{"month":3,"riseRate":0.4,"avgChangeRate":0.087947},{"month":4,"riseRate":0.2,"avgChangeRate":-0.108991},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018168},{"month":6,"riseRate":0.8,"avgChangeRate":0.125791},{"month":7,"riseRate":0.5,"avgChangeRate":0.140277},{"month":8,"riseRate":0.5,"avgChangeRate":0.010964},{"month":9,"riseRate":0.2,"avgChangeRate":-0.055084},{"month":10,"riseRate":0.8,"avgChangeRate":0.03327},{"month":11,"riseRate":0.6,"avgChangeRate":0.082541},{"month":12,"riseRate":0.6,"avgChangeRate":0.051049}],"exchange":"NASDAQ","name":"BridgeBio Pharma, Inc.","nameEN":"BridgeBio Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BridgeBio Pharma, Inc.,BBIO,BridgeBio Pharma, Inc.股票,BridgeBio Pharma, Inc.股票老虎,BridgeBio Pharma, Inc.股票老虎国际,BridgeBio Pharma, Inc.行情,BridgeBio Pharma, Inc.股票行情,BridgeBio Pharma, Inc.股价,BridgeBio Pharma, Inc.股市,BridgeBio Pharma, Inc.股票价格,BridgeBio Pharma, Inc.股票交易,BridgeBio Pharma, Inc.股票购买,BridgeBio Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况